12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga · 03/28 21:05
Gainers
- Biodesix (NASDAQ:BDSX) shares rose 11.9% to $0.75 during Friday's after-market session. The company's market cap stands at $108.8 million.
- Know Labs (AMEX:KNW) shares moved upwards by 10.96% to $0.81. The market value of their outstanding shares is at $2.2 million.
- Gelteq (NASDAQ:GELS) shares increased by 10.0% to $1.1. The market value of their outstanding shares is at $10.3 million.
- bluebird bio (NASDAQ:BLUE) stock increased by 9.8% to $4.48. The company's market cap stands at $43.6 million. As per the press release, Q4 earnings came out yesterday.
- Molecular Partners (NASDAQ:MOLN) shares increased by 9.75% to $4.5. The market value of their outstanding shares is at $165.9 million.
- Century Therapeutics (NASDAQ:IPSC) shares rose 8.89% to $0.56. The market value of their outstanding shares is at $48.0 million.
Losers
- LogicMark (NASDAQ:LGMK) shares fell 20.5% to $0.02 during Friday's after-market session.
- GlucoTrack (NASDAQ:GCTK) stock fell 16.83% to $0.17. The market value of their outstanding shares is at $2.2 million.
- 23andMe Holding (NASDAQ:ME) stock decreased by 14.57% to $0.52. The market value of their outstanding shares is at $13.8 million.
- Enzo Biochem (NYSE:ENZ) shares decreased by 14.26% to $0.37. The market value of their outstanding shares is at $19.3 million.
- Qualigen Therapeutics (NASDAQ:QLGN) stock decreased by 13.39% to $3.3. The company's market cap stands at $2.4 million.
- Ocean Biomedical (NASDAQ:OCEA) shares fell 11.95% to $0.06. The market value of their outstanding shares is at $7.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.